<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796170</url>
  </required_header>
  <id_info>
    <org_study_id>812701</org_study_id>
    <nct_id>NCT02796170</nct_id>
  </id_info>
  <brief_title>Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes</brief_title>
  <official_title>Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tulane University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of SGLT-2 inhibitors on blood pressure and urinary angiotensinogen. This&#xD;
      is a cross over study design, where 40 subjects will receive Dapagliflozin for 6 weeks&#xD;
      followed by placebo for 6 weeks, or placebo for 6 weeks followed by Dapagliflozin for 6&#xD;
      weeks. In addition there will be an arm of 10 subjects who will receive sulfonylurea in an&#xD;
      open label as a comparative to the cross over subjects to assess if the effect of&#xD;
      Dapagliflozin may also be in part due to improved glycemic control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical trials of two SGLT2 inhibitors, canagliflozin and dapagliflozin, have reported drops&#xD;
      in systolic blood pressure of ~5 mmHg. Inappropriate activation of intrarenal&#xD;
      renin-angiotensin system (RAS) is a major contributor to the increased arterial pressure and&#xD;
      tissue injury including diabetic nephropathy. A key factor in the intrarenal RAS activation&#xD;
      is stimulation of intrarenal angiotensinogen (AGT) which is the precursor of angiotensin&#xD;
      peptides. From previous studies, it has been shown that high blood sugars in patients with&#xD;
      type1 and type 2 diabetes mellitus is accompanied by elevated intrarenal AGT and urinary AGT&#xD;
      levels. High glucose results in stimulation of AGT production. The high glucose levels&#xD;
      augments intrarenal AGT levels in diabetes mellitus leading to the development of high blood&#xD;
      pressure and diabetic nephropathy.&#xD;
&#xD;
      The investigators propose to conduct a single-center randomized, double blind, cross over&#xD;
      study of the effect of Dapagliflozin over 6 weeks, followed by placebo over 6 weeks on the&#xD;
      other treatment allocation (those getting placebo first will cross over to Dapagliflozin and&#xD;
      vice versa). Treatment will be stratified according to the underlying presence or absence of&#xD;
      hypertension.&#xD;
&#xD;
        1. Type 2 diabetes with hypertension and on RAAS blocking drugs with stable blood pressure&#xD;
           on therapy; n= 20&#xD;
&#xD;
        2. Type 2 diabetes without hypertension and not on RAAS blocking drugs n=10&#xD;
&#xD;
      If unable to recruit 10 participants without hypertension the investigators will increase the&#xD;
      number with hypertension for a total of 30. Stratification by hypertension status will remain&#xD;
      and is important in understanding the effect of SGLT2 inhibition in patients not on BP&#xD;
      lowering drugs.&#xD;
&#xD;
      In addition a Sulfonylurea (SU) arm will also be included - 10 participants who are on&#xD;
      metformin and other background therapy (with the exclusion of SGLT-2 inhibitor and&#xD;
      sulfonylurea) will be recruited. This will be an open-labeled arm. Participants will assessed&#xD;
      at baseline. Participants will then receive usual care for 6 weeks. At the end of 6 weeks,&#xD;
      participants will then undergo another assessment before being provided SU for 6 weeks. At&#xD;
      the end of 6 weeks, participants will undergo assessment again. The aim is to determine&#xD;
      whether any effects seen with Dapagliflozin are specific to that drug or related simply to&#xD;
      improved glycemic control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">August 2020</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood pressure from baseline to 6 weeks</measure>
    <time_frame>baseline to 6 weeks</time_frame>
    <description>Blood pressure will be measured at baseline with a 24 hour ambulatory blood pressure machine, and again after 6 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in urinary AGT levels from baseline to 6 weeks</measure>
    <time_frame>baseline to 6 weeks</time_frame>
    <description>Urinary AGT will be measure through the collection of 24 hour urine at baseline and again after 6 weeks of treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will undergo 6 weeks of Dapagloflozin then 6 weeks of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfonylurea</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm will be open label, participants will receive usual care for 6 weeks, then be provided a sulfonylurea medication for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will undergo 6 weeks of placebo then 6 weeks of Dapagloflozin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>5mg pill taken once daily</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfonylurea</intervention_name>
    <description>Subjects may take any of the sulfonlyurea medications, titration will be done per standard of care.</description>
    <arm_group_label>Sulfonylurea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5mg pill taken once daily- placebo of Dapagliflozin</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes with hypertension and on RAAS blocking drugs OR&#xD;
&#xD;
          -  Type 2 diabetes without hypertension and not on RAAS blocking drugs&#xD;
&#xD;
          -  Hemoglobin A1c between 7% and 9% (inclusive)&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) ≥60 ml/min&#xD;
&#xD;
          -  Capacity to understand and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe hepatic insufficiency and/or significant abnormal liver function defined as AST&#xD;
             and/or ALT &gt;3x ULN&#xD;
&#xD;
          -  Total bilirubin &gt;2.0 mg/dL&#xD;
&#xD;
          -  Positive serologic evidence of current infectious liver disease, including Hepatitis B&#xD;
             viral antibody IGM, Hepatitis B surface antigen, and Hepatitis C virus antibody&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt;60 ml/min&#xD;
&#xD;
          -  Recent cardiovascular events with the last 2 months: acute coronary syndrome (ACS),&#xD;
             hospitalization for unstable angina or acute myocardial infarction, acute stroke or&#xD;
             TIA, or post coronary artery revascularization&#xD;
&#xD;
          -  Congestive Heart Failure defined as New York Heart Association (NYHA) class IV,&#xD;
             unstable or acute congestive heart failure&#xD;
&#xD;
          -  Pregnant or breastfeeding patients&#xD;
&#xD;
          -  Patients who, in the judgement of the investigator, may be at risk for dehydration&#xD;
&#xD;
          -  Blood pressure at enrollment: Systolic ≥165 mmHg and/or Diastolic ≥110 mmHg; At&#xD;
             randomization: Systolic ≥160 mmHg and/or Diastolic ≥100 mmHg&#xD;
&#xD;
          -  Use of SGLT-2 inhibitor class drugs is an exclusion for all patients. For patients in&#xD;
             the sulfonylurea arm, use of sulfonylurea class drugs is an exclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dragana Lovre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tina Thethi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AdventHealth</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 26, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <disposition_first_submitted>February 1, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>February 4, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 8, 2021</disposition_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SGLT-2 inhibitor</keyword>
  <keyword>urinary angiotensinogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

